Patients will receive duvelisib administered orally BID in a 28-day treatment cycle.

2 trials

Sponsors

Suzuki Kenta, Hiroki Kageyama

Conditions

Adult T-cell leukemia/lymphomaFollicular lymphoma

Phase 2

A Phase II Study of YHI-1702

Active, not recruitingJPRN-jRCT2031210529

Suzuki KentaFollicular lymphoma

Start: 2022-05-26Target: 36Updated: 2026-06-29

A Phase II Study of YHI-1702

Active, not recruitingJPRN-jRCT2071210133

Hiroki KageyamaAdult T-cell leukemia/lymphoma

Start: 2022-04-01Target: 21Updated: 2026-06-29